vs
Side-by-side financial comparison of ROGERS CORP (ROG) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $158.6M, roughly 1.3× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 2.2%, a 68.9% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 5.2%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $1.1M).
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
ROG vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $200.5M | $158.6M |
| Net Profit | $4.5M | $112.9M |
| Gross Margin | 32.2% | — |
| Operating Margin | — | 70.2% |
| Net Margin | 2.2% | 71.2% |
| Revenue YoY | 5.2% | 3661.1% |
| Net Profit YoY | 421.4% | 528.0% |
| EPS (diluted) | $0.25 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $200.5M | — | ||
| Q4 25 | $201.5M | — | ||
| Q3 25 | $216.0M | — | ||
| Q2 25 | $202.8M | — | ||
| Q1 25 | $190.5M | $158.6M | ||
| Q4 24 | $192.2M | $22.6M | ||
| Q3 24 | $210.3M | — | ||
| Q2 24 | $214.2M | — |
| Q1 26 | $4.5M | — | ||
| Q4 25 | $4.6M | — | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $-73.6M | — | ||
| Q1 25 | $-1.4M | $112.9M | ||
| Q4 24 | $-500.0K | $-10.5M | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $8.1M | — |
| Q1 26 | 32.2% | — | ||
| Q4 25 | 31.5% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 31.6% | — | ||
| Q1 25 | 29.9% | — | ||
| Q4 24 | 32.1% | — | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | 34.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.5% | — | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | -33.3% | — | ||
| Q1 25 | -0.2% | 70.2% | ||
| Q4 24 | -6.6% | -60.4% | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 5.3% | — |
| Q1 26 | 2.2% | — | ||
| Q4 25 | 2.3% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | -36.3% | — | ||
| Q1 25 | -0.7% | 71.2% | ||
| Q4 24 | -0.3% | -46.4% | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 3.8% | — |
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.48 | — | ||
| Q2 25 | $-4.00 | — | ||
| Q1 25 | $-0.08 | $1.90 | ||
| Q4 24 | $-0.04 | $-0.15 | ||
| Q3 24 | $0.58 | — | ||
| Q2 24 | $0.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.8M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $350.1M |
| Total Assets | $1.4B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $195.8M | — | ||
| Q4 25 | $197.0M | — | ||
| Q3 25 | $167.8M | — | ||
| Q2 25 | $157.2M | — | ||
| Q1 25 | $175.6M | $274.8M | ||
| Q4 24 | $159.8M | $128.0M | ||
| Q3 24 | $146.4M | — | ||
| Q2 24 | $119.9M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | $350.1M | ||
| Q4 24 | $1.3B | $229.0M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | $406.9M | ||
| Q4 24 | $1.5B | $271.6M | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $131.8M |
| Free Cash FlowOCF − Capex | $1.1M | $131.7M |
| FCF MarginFCF / Revenue | 0.5% | 83.0% |
| Capex IntensityCapex / Revenue | 2.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.29× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $70.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.8M | — | ||
| Q4 25 | $46.9M | — | ||
| Q3 25 | $28.9M | — | ||
| Q2 25 | $13.7M | — | ||
| Q1 25 | $11.7M | $131.8M | ||
| Q4 24 | $33.7M | $-23.2M | ||
| Q3 24 | $42.4M | — | ||
| Q2 24 | $22.9M | — |
| Q1 26 | $1.1M | — | ||
| Q4 25 | $42.2M | — | ||
| Q3 25 | $21.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $2.1M | $131.7M | ||
| Q4 24 | $18.3M | $-23.2M | ||
| Q3 24 | $25.2M | — | ||
| Q2 24 | $8.8M | — |
| Q1 26 | 0.5% | — | ||
| Q4 25 | 20.9% | — | ||
| Q3 25 | 9.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 1.1% | 83.0% | ||
| Q4 24 | 9.5% | -102.7% | ||
| Q3 24 | 12.0% | — | ||
| Q2 24 | 4.1% | — |
| Q1 26 | 2.3% | — | ||
| Q4 25 | 2.3% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | 0.1% | ||
| Q4 24 | 8.0% | 0.2% | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 6.6% | — |
| Q1 26 | 1.29× | — | ||
| Q4 25 | 10.20× | — | ||
| Q3 25 | 3.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.96× | — | ||
| Q2 24 | 2.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
